Alaunos Therapeutics (TCRT) Competitors $5.01 -0.05 (-0.89%) Closing price 02:08 PM EasternExtended Trading$5.01 0.00 (0.00%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TCRT vs. NRSN, GRCE, MRNS, MAAQ, ALLK, DYAI, INKT, SCYX, SXTC, and RANIShould you be buying Alaunos Therapeutics stock or one of its competitors? The main competitors of Alaunos Therapeutics include NeuroSense Therapeutics (NRSN), Grace Therapeutics (GRCE), Marinus Pharmaceuticals (MRNS), Mana Capital Acquisition (MAAQ), Allakos (ALLK), Dyadic International (DYAI), MiNK Therapeutics (INKT), SCYNEXIS (SCYX), China SXT Pharmaceuticals (SXTC), and Rani Therapeutics (RANI). These companies are all part of the "pharmaceutical products" industry. Alaunos Therapeutics vs. Its Competitors NeuroSense Therapeutics Grace Therapeutics Marinus Pharmaceuticals Mana Capital Acquisition Allakos Dyadic International MiNK Therapeutics SCYNEXIS China SXT Pharmaceuticals Rani Therapeutics NeuroSense Therapeutics (NASDAQ:NRSN) and Alaunos Therapeutics (NASDAQ:TCRT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings, media sentiment and risk. Which has more risk & volatility, NRSN or TCRT? NeuroSense Therapeutics has a beta of 1.66, suggesting that its stock price is 66% more volatile than the S&P 500. Comparatively, Alaunos Therapeutics has a beta of -0.79, suggesting that its stock price is 179% less volatile than the S&P 500. Do institutionals & insiders have more ownership in NRSN or TCRT? 1.0% of NeuroSense Therapeutics shares are owned by institutional investors. Comparatively, 27.7% of Alaunos Therapeutics shares are owned by institutional investors. 27.4% of NeuroSense Therapeutics shares are owned by company insiders. Comparatively, 16.1% of Alaunos Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is NRSN or TCRT more profitable? NeuroSense Therapeutics' return on equity of 0.00% beat Alaunos Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets NeuroSense TherapeuticsN/A N/A -445.40% Alaunos Therapeutics N/A -169.34%-124.28% Do analysts rate NRSN or TCRT? NeuroSense Therapeutics presently has a consensus target price of $14.00, suggesting a potential upside of 632.98%. Given NeuroSense Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe NeuroSense Therapeutics is more favorable than Alaunos Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NeuroSense Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.00Alaunos Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media prefer NRSN or TCRT? In the previous week, NeuroSense Therapeutics and NeuroSense Therapeutics both had 1 articles in the media. Alaunos Therapeutics' average media sentiment score of 0.19 beat NeuroSense Therapeutics' score of 0.00 indicating that Alaunos Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeuroSense Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alaunos Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has preferable valuation & earnings, NRSN or TCRT? Alaunos Therapeutics has higher revenue and earnings than NeuroSense Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeuroSense TherapeuticsN/AN/A-$10.21M-$0.54-3.54Alaunos Therapeutics$10K822.46-$4.68MN/AN/A SummaryNeuroSense Therapeutics beats Alaunos Therapeutics on 7 of the 13 factors compared between the two stocks. Get Alaunos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TCRT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TCRT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TCRT vs. The Competition Export to ExcelMetricAlaunos TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.30M$2.44B$5.54B$8.95BDividend YieldN/A1.77%5.38%4.08%P/E Ratio-1.978.8627.4020.04Price / Sales822.46680.42419.46118.60Price / CashN/A157.0736.6357.47Price / Book3.894.638.085.67Net Income-$4.68M$31.34M$3.16B$248.47M7 Day Performance-0.10%0.84%2.12%2.90%1 Month Performance79.75%7.92%4.43%5.75%1 Year Performance-20.40%1.87%35.62%21.36% Alaunos Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TCRTAlaunos Therapeutics0.8065 of 5 stars$5.02-0.9%N/A-19.7%$8.30M$10K-1.9740News CoverageGap DownNRSNNeuroSense Therapeutics1.721 of 5 stars$2.31+8.5%$14.00+506.1%+53.2%$31.58MN/A-4.2810News CoverageGRCEGrace Therapeutics1.7875 of 5 stars$3.00+2.4%$12.00+300.0%N/A$30.42MN/A-2.59N/APositive NewsMRNSMarinus Pharmaceuticals2.3574 of 5 stars$0.55-0.2%$3.92+613.3%-53.9%$30.32M$30.99M-0.22110MAAQMana Capital AcquisitionN/A$3.70-0.3%N/A+556.4%$30.06MN/A0.001ALLKAllakos2.8934 of 5 stars$0.33flat$2.00+507.7%N/A$29.74MN/A-0.16190DYAIDyadic International2.0269 of 5 stars$0.99+5.1%$6.00+508.6%-35.2%$29.66M$3.49M-4.937News CoverageGap DownINKTMiNK Therapeutics3.2771 of 5 stars$7.30-2.4%$37.50+413.7%-18.3%$29.13MN/A-2.9030SCYXSCYNEXIS0.2783 of 5 stars$0.74+1.5%N/A-63.1%$28.92M$3.75M-1.3260SXTCChina SXT Pharmaceuticals0.1623 of 5 stars$1.81-1.6%N/A-79.4%$28.65M$1.93M0.0090RANIRani Therapeutics1.5263 of 5 stars$0.50+1.4%$7.33+1,376.1%-86.3%$28.56M$1.03M-0.50110 Related Companies and Tools Related Companies NeuroSense Therapeutics Alternatives Grace Therapeutics Alternatives Marinus Pharmaceuticals Alternatives Mana Capital Acquisition Alternatives Allakos Alternatives Dyadic International Alternatives MiNK Therapeutics Alternatives SCYNEXIS Alternatives China SXT Pharmaceuticals Alternatives Rani Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TCRT) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe $100 Trillion AI Story No One Is Telling YouJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alaunos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alaunos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
